Ravalet Noémie, Foucault Amélie, Picou Frédéric, Gombert Martin, Renoult Emmanuel, Lejeune Julien, Vallet Nicolas, Lachot Sébastien, Rault Emmanuelle, Gyan Emmanuel, Bene Marie C, Herault Olivier
Department of Biological Hematology, Tours University Hospital, 37000 Tours, France.
CNRS ERL 7001 LNOX, EA7501, Faculty of Medidine, Tours University, 37000 Tours, France.
Cancers (Basel). 2021 Jan 21;13(3):389. doi: 10.3390/cancers13030389.
The incidence of myelodysplastic syndrome increases with aging and the early diagnosis enables optimal care of these diseases. The DxH 800 hematology analyzer measures and calculates 126 cytological parameters, but only 23 are used for routine CBC assessment. The goal of this study was to use the 103 unexploited "research parameters" to develop an algorithm allowing for an early detection of subclinical MDS patients by triggering morphological analysis. Blood sample parameters from 101 MDS patients and 88 healthy volunteers were analyzed to identify the critical "research parameters" with: (i) the most significant differences between MDS patients and healthy volunteers, (ii) the best contributions to principal component analysis (PCA), first axis, and (iii) the best correlations with PCA, first two axes (cos > 0.6). Ten critical "research parameters" of white blood cells were identified, allowing for the calculation of an MDS-likelihood score (MDS-LS), based on logistic regression. Automatic calculation of the MDS-LS is easily implementable on the middleware system of the DxH 800 to generate a flag for blood smear review, and possibly early detection of MDS patients in the general population.
骨髓增生异常综合征的发病率随年龄增长而增加,早期诊断有助于对这些疾病进行最佳治疗。DxH 800血液分析仪可测量并计算126个细胞学参数,但常规全血细胞计数评估仅使用其中23个参数。本研究的目的是利用103个未被利用的“研究参数”开发一种算法,通过触发形态学分析来早期检测亚临床骨髓增生异常综合征患者。分析了101例骨髓增生异常综合征患者和88名健康志愿者的血样参数,以确定关键的“研究参数”,这些参数需满足:(i)骨髓增生异常综合征患者与健康志愿者之间差异最为显著;(ii)对主成分分析(PCA)第一轴贡献最大;(iii)与PCA前两轴相关性最佳(cos > 0.6)。确定了10个白细胞关键“研究参数”,基于逻辑回归计算骨髓增生异常综合征可能性评分(MDS-LS)。MDS-LS的自动计算可轻松在DxH 800的中间件系统上实现,以生成血涂片复查标记,可能有助于在普通人群中早期检测骨髓增生异常综合征患者。